HRP20221447T1 - Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe - Google Patents
Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20221447T1 HRP20221447T1 HRP20221447TT HRP20221447T HRP20221447T1 HR P20221447 T1 HRP20221447 T1 HR P20221447T1 HR P20221447T T HRP20221447T T HR P20221447TT HR P20221447 T HRP20221447 T HR P20221447T HR P20221447 T1 HRP20221447 T1 HR P20221447T1
- Authority
- HR
- Croatia
- Prior art keywords
- fusion protein
- seq
- protein according
- subject
- amino acid
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 27
- 102000037865 fusion proteins Human genes 0.000 title claims 27
- 238000000034 method Methods 0.000 title claims 7
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 238000004806 packaging method and process Methods 0.000 claims 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 101100335897 Caenorhabditis elegans gly-9 gene Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Claims (17)
1. Fuzijski protein koji sadrži (a) izvanstanični dio beta receptora faktora rasta izvedenog iz trombocita (PDGFRβ) koji sadrži Ig-slične domene D1-D3 PDGFRβ, (b) izvanstanični dio receptora faktora rasta vaskularnog endotela (VEGF), i (c) multimerizacijsku domenu koja sadrži Fc regiju IgG1 protutijela, pri čemu se fuzijski protein veže na PDGF i VEGF, pri čemu je fuzijski protein raspoređen od N-kraja do C-kraja sljedećim redoslijedom: (a), (b) and (c), pri čemu fuzijski protein sadrži vezni peptid između (a) i (b) koji sadrži Ser9 (SEQ ID NO: 49), pri čemu fuzijski protein sadrži poveznicu između (b) i (c) koja sadrži Gly9 (SEQ ID NO: 47), te pri čemu se izvanstanični dio VEGF receptora sastoji od Ig-slične domene D2.
2. Fuzijski protein prema zahtjevu 1, naznačen time što izvanstanični dio PDGFR sadrži:
(a) Ig-slične domene D1-D5 PDGFRβ;
(b) aminokiselinsku sekvencu koja ima najmanje 85% identičnosti sa SEQ ID NO: 1 ili 3; ili
(c) aminokiselinsku sekvencu SEQ ID NO:1 ili 3.
3. Fuzijski protein prema zahtjevu 1 ili zahtjevu 2, naznačen time što izvanstanični dio receptora VEGF sadrži:
(a) aminokiselinsku sekvencu koja ima najmanje 85% identičnosti sa SEQ ID NO:4; ili
(b) aminokiselinsku sekvencu SEQ ID NO:4.
4. Fuzijski protein prema bilo kojem od zahtjeva 1-3, naznačen time što multimerizacijska domena sadrži:
(a) aminokiselinsku sekvencu koja ima najmanje 85% identičnosti sa SEQ ID NO:6; ili
(b) aminokiselinsku sekvencu SEQ ID NO:6.
5. Fuzijski protein prema bilo kojem od zahtjeva 1-4, naznačen time što fuzijski protein sadrži aminokiselinsku sekvencu SEQ ID NO: 13, 15, 43 ili 45 aminokiselinsku sekvencu koja ima najmanje 85% identičnosti sa SEQ ID NO:13, 15, 43 ili 45.
6. Fuzijski protein prema bilo kojem od zahtjeva 1-5, naznačen time što je fuzijski protein u dimernom ili multimernom obliku.
7. Pripravak naznačen time što sadrži fuzijski protein prema bilo kojem od zahtjeva 1-6 i farmaceutski prihvatljiv nosač.
8. Nukleinska kiselina naznačena time što kodira fuzijski protein prema bilo kojem od zahtjeva 1-5.
9. Stanica domaćina naznačena time što sadrži nukleotidnu sekvencu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-5.
10. Postupak proizvodnje fuzijskog proteina, naznačen time što obuhvaća uzgoj stanice domaćina koja sadrži nukleinsku kiselinu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-5 pod uvjetima koji proizvode fuzijski protein, te obnavljanje fuzijskog proteina proizvedenog pomoću stanice domaćina.
11. Fuzijski protein prema bilo kojem zahtjevu 1-6 za upotrebu u postupke liječenja bolesti kod subjekta, pri čemu postupak uključuje davanje učinkovite količine fuzijskog proteina subjektu.
12. Fuzijski protein za upotrebu prema zahtjevu 11, naznačen time što subjekt ima makularnu degeneraciju, vlažnu makularnu povezanu sa starenjem, suhu makularnu degeneraciju povezanu sa starenjem, proliferativnu dijabetičku retinopatiju, rak, reumatoidni artritis, osteoartritis, astmu, uveitis ili neovaskularizaciju rožnice, te pri čemu se fuzijski protein po izboru daje subjektu intravitrealnom injekcijom.
13. Vektor naznačen time što sadrži nukleotidnu sekvencu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-5.
14. Čestica rekombinantnog adeno-pridruženog virusnog vektora (rAAV) koja sadrži nukleinsku kiselinu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-5.
15. Postupak proizvodnje rAAV čestice, naznačen time što sadrži:
(a) uzgoj stanice domaćina pod uvjetom da se proizvode rAAV čestice, pri čemu stanica domaćina sadrži (i) jedan ili više gena za pakiranje AAV, pri čemu svaki navedeni gen za pakiranje AAV kodira protein replikacije ili inkapsidacije; (ii) rAAV pro-vektor koji sadrži nukleotid koji kodira fuzijski protein prema bilo kojem od zahtjeva 1-5 na svakoj strani s najmanje jednim AAV ITR, and (iii) AAV pomoćnu funkciju; i
(b) obnavljanje čestica rAAV koje proizvodi stanica domaćin.
16. Čestica rAAV prema zahtjevu 14, naznačena time što se koristi u postupku liječenja bolesti kod subjekta, pri čemu postupka obuhvaća davanje subjektu učinkovite količine čestice rAAV.
17. Čestica rAAV za upotrebu prema zahtjevu 16, naznačena time što subjekt ima makularnu degeneraciju, vlažnu makularnu degeneraciju povezanu sa starenjem, suhu makularnu degeneraciju povezanu sa starenjem, proliferativnu dijabetičku retinopatiju, rak, reumatoidni artritis, osteoartritis, astmu, uveitis ili neovaskularizaciju rožnice, te pri čemu se čestica rAAV po izboru daje subjektu intravitrealnom injekcijom.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780914P | 2013-03-13 | 2013-03-13 | |
PCT/US2014/026872 WO2014160507A1 (en) | 2013-03-13 | 2014-03-13 | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
EP14722439.8A EP2968461B1 (en) | 2013-03-13 | 2014-03-13 | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221447T1 true HRP20221447T1 (hr) | 2023-01-20 |
Family
ID=50680144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221447TT HRP20221447T1 (hr) | 2013-03-13 | 2014-03-13 | Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe |
Country Status (27)
Country | Link |
---|---|
US (4) | US9637534B2 (hr) |
EP (1) | EP2968461B1 (hr) |
JP (2) | JP6561042B2 (hr) |
KR (1) | KR102228921B1 (hr) |
CN (1) | CN105188733B (hr) |
AR (1) | AR095437A1 (hr) |
AU (2) | AU2014243712B2 (hr) |
BR (1) | BR112015022208A8 (hr) |
CA (1) | CA2904623A1 (hr) |
DK (1) | DK2968461T3 (hr) |
ES (1) | ES2933558T3 (hr) |
FI (1) | FI2968461T3 (hr) |
HK (1) | HK1220618A1 (hr) |
HR (1) | HRP20221447T1 (hr) |
HU (1) | HUE060464T2 (hr) |
IL (2) | IL240950B (hr) |
LT (1) | LT2968461T (hr) |
MX (1) | MX363533B (hr) |
PL (1) | PL2968461T3 (hr) |
PT (1) | PT2968461T (hr) |
RS (1) | RS63820B1 (hr) |
RU (1) | RU2692652C2 (hr) |
SG (3) | SG10201912956YA (hr) |
SI (1) | SI2968461T1 (hr) |
TW (1) | TWI631133B (hr) |
UY (1) | UY35407A (hr) |
WO (1) | WO2014160507A1 (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
PT2968461T (pt) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização |
EP3010525A1 (en) * | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating choroidal neovascularisation |
PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
WO2015140638A1 (en) | 2014-03-18 | 2015-09-24 | Korea Advanced Institute Of Science And Technology (Kaist) | Glycosylated vegf decoy receptor fusion protein |
WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
SG11201705271YA (en) | 2015-03-11 | 2017-07-28 | Allgenesis Biotherapeutics Inc | Fusion protein comprising a ligand binding domain of vegf and pdgf |
CN108430489B (zh) * | 2015-06-28 | 2022-03-25 | 新源生物科技股份有限公司 | 用于抑制血管新生的融合蛋白 |
CA3005391A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
CA3019530A1 (en) | 2016-03-30 | 2017-10-05 | Ab Biosciences, Inc. | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
JP6849390B2 (ja) * | 2016-10-28 | 2021-03-24 | 花王株式会社 | 関節のこわばり改善剤 |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
WO2019083171A2 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물 |
CN111406071B (zh) * | 2017-11-16 | 2024-01-16 | 成都硕德药业有限公司 | Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途 |
WO2019096226A1 (en) | 2017-11-16 | 2019-05-23 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Pasylated vegfr/pdgfr fusion proteins and their use in therapy |
CN116059318A (zh) * | 2018-01-26 | 2023-05-05 | 加利福尼亚大学董事会 | 用于使用抗vegf剂治疗血管生成病症的方法和组合物 |
US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
KR20220104756A (ko) | 2019-11-25 | 2022-07-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제 |
WO2021112597A1 (ko) * | 2019-12-04 | 2021-06-10 | 주식회사 씨드모젠 | 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 당뇨망막병증 치료용 조성물 |
CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
CN113105558A (zh) * | 2021-04-01 | 2021-07-13 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法 |
EP4355767A1 (en) * | 2021-06-18 | 2024-04-24 | Ikarovec Limited | Retinal disorders |
WO2023199951A1 (ja) * | 2022-04-13 | 2023-10-19 | 株式会社セルージョン | 抗vegf機能を有する多能性幹細胞及びその分化細胞 |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
WO2024029876A1 (ko) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4454151A (en) | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4952515A (en) | 1987-05-22 | 1990-08-28 | Polymer Technology International Corp. | Method of detection using a test strip having a non particulate dialyzed polymer layer |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
WO1992013867A1 (en) | 1991-01-31 | 1992-08-20 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
CA2410828C (en) | 2000-06-01 | 2012-01-24 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US20030181531A1 (en) | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
AU2003218168A1 (en) | 2002-03-15 | 2003-09-29 | University Of Southern California | Ophthalmic solutions for delivery of expression vectors |
US20040058313A1 (en) | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
CN101094688B (zh) | 2004-09-13 | 2013-05-01 | 建新公司 | 多聚构建体 |
US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
DE102005020510A1 (de) | 2005-04-29 | 2006-11-09 | Basf Ag | Verbundelement, insbesondere Fensterscheibe |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN101951925A (zh) | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
PL2274008T3 (pl) | 2008-03-27 | 2014-07-31 | Zymogenetics Inc | Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
CN102311502B (zh) * | 2010-07-10 | 2013-12-25 | 成都康弘生物科技有限公司 | 一种抑制血管新生或生长的融合蛋白及其医疗应用 |
WO2012075184A2 (en) * | 2010-12-02 | 2012-06-07 | Neurotech Usa, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
PT2968461T (pt) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização |
-
2014
- 2014-03-13 PT PT147224398T patent/PT2968461T/pt unknown
- 2014-03-13 LT LTEPPCT/US2014/026872T patent/LT2968461T/lt unknown
- 2014-03-13 KR KR1020157027849A patent/KR102228921B1/ko active IP Right Grant
- 2014-03-13 AU AU2014243712A patent/AU2014243712B2/en active Active
- 2014-03-13 HR HRP20221447TT patent/HRP20221447T1/hr unknown
- 2014-03-13 PL PL14722439.8T patent/PL2968461T3/pl unknown
- 2014-03-13 MX MX2015011951A patent/MX363533B/es unknown
- 2014-03-13 CA CA2904623A patent/CA2904623A1/en not_active Abandoned
- 2014-03-13 SI SI201432005T patent/SI2968461T1/sl unknown
- 2014-03-13 RU RU2015142999A patent/RU2692652C2/ru active
- 2014-03-13 SG SG10201912956YA patent/SG10201912956YA/en unknown
- 2014-03-13 US US14/210,354 patent/US9637534B2/en active Active
- 2014-03-13 EP EP14722439.8A patent/EP2968461B1/en active Active
- 2014-03-13 FI FIEP14722439.8T patent/FI2968461T3/fi active
- 2014-03-13 AR ARP140100983A patent/AR095437A1/es unknown
- 2014-03-13 SG SG11201506802SA patent/SG11201506802SA/en unknown
- 2014-03-13 WO PCT/US2014/026872 patent/WO2014160507A1/en active Application Filing
- 2014-03-13 DK DK14722439.8T patent/DK2968461T3/da active
- 2014-03-13 BR BR112015022208A patent/BR112015022208A8/pt not_active IP Right Cessation
- 2014-03-13 SG SG10201707501TA patent/SG10201707501TA/en unknown
- 2014-03-13 RS RS20221155A patent/RS63820B1/sr unknown
- 2014-03-13 TW TW103109211A patent/TWI631133B/zh not_active IP Right Cessation
- 2014-03-13 JP JP2016502268A patent/JP6561042B2/ja active Active
- 2014-03-13 CN CN201480026585.2A patent/CN105188733B/zh active Active
- 2014-03-13 ES ES14722439T patent/ES2933558T3/es active Active
- 2014-03-13 HU HUE14722439A patent/HUE060464T2/hu unknown
- 2014-03-13 UY UY0001035407A patent/UY35407A/es not_active Application Discontinuation
-
2015
- 2015-08-31 IL IL240950A patent/IL240950B/en active IP Right Grant
-
2016
- 2016-07-20 HK HK16108675.7A patent/HK1220618A1/zh unknown
-
2017
- 2017-03-28 US US15/471,725 patent/US10183983B2/en active Active
-
2018
- 2018-11-20 US US16/197,194 patent/US11084864B2/en active Active
- 2018-12-12 AU AU2018278902A patent/AU2018278902A1/en not_active Abandoned
-
2019
- 2019-02-04 JP JP2019017599A patent/JP2019123711A/ja active Pending
- 2019-05-19 IL IL266715A patent/IL266715A/en unknown
-
2021
- 2021-07-02 US US17/367,027 patent/US20220064262A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221447T1 (hr) | Fuzijski proteini koji sadrže dijelove za vezanje pdgf i vegf i postupci njihove upotrebe | |
JP2016513669A5 (hr) | ||
JP7229298B2 (ja) | 2種の抗体構築物を発現するaavを含む組成物およびこの使用 | |
CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
ES2916468T3 (es) | Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento | |
JP2020028308A5 (hr) | ||
FI3645553T3 (fi) | Tropismilla muokattuja rekombinantteja viruspartikkeleita ja niiden käyttöjä geneettisen materiaalin viemiseksi kohdennetusti ihmissoluihin | |
JP2014519830A5 (hr) | ||
JP2015500811A5 (hr) | ||
HRP20161531T1 (hr) | Fc fuzijski proteini koji sadrže nove linkere ili aranžmane | |
JP2014515602A5 (hr) | ||
HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
JP2013537416A5 (hr) | ||
WO2012159006A8 (en) | Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof | |
JP2014504150A5 (hr) | ||
JP2017514522A5 (hr) | ||
HRP20200477T1 (hr) | Kimerni protein sastavljen od domene antagonista ngf i domene antagonista tnfa | |
CN103965362B (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
JP2014530001A5 (hr) | ||
CN111132993A (zh) | 合理设计的用于调节嵌合抗原受体(car)-t细胞疗法的病毒样颗粒 | |
CN109641949A (zh) | 促进选择性轻链配对的多特异性抗体 | |
CN117083297A (zh) | 抗PD-L1单克隆抗体以及与白细胞介素-15(IL-15)、白细胞介素-15受体15α或白细胞介素-2的融合蛋白 | |
US20140350225A1 (en) | Anti-bfgf humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof | |
KR20230172538A (ko) | Fc-유래된 폴리펩티드 | |
JP7381604B2 (ja) | 癌を治療するための多価pd-l1結合化合物 |